Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma.
Teiji KuzuyaMasatoshi IshigamiTakanori ItoYoji IshizuTakashi HondaTetsuya IshikawaMitsuhiro FujishiroPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2019)
The radiological antitumor response at 2 weeks was favorable. Information on a favorable visible therapeutic response very early after lenvatinib initiation can help patients maintain their motivation for treatment, and allow physicians to continue treatment effectively and safely.